Oncolys BioPharma (TSE:4588) Institutional Ownership: 0.28% (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4588 Oncolys BioPharma Inc TSE:4588
40 GF Score
Price 円3,490.00
GF Value 円355.75
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Oncolys BioPharma Institutional Ownership?

Oncolys BioPharma TSE:4588 +7.38% 40 Institutional Ownership is 0.28% as of Aug. 17, 2026. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円355.75 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oncolys BioPharma's institutional ownership is 0.28%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oncolys BioPharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oncolys BioPharma's Float Percentage Of Total Shares Outstanding is 0.00%.

Oncolys BioPharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Oncolys BioPharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolys BioPharma Institutional Ownership Chart

Oncolys BioPharma Historical Data

The historical data trend for Oncolys BioPharma can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 0.31 0.31 0.30 0.27 0.40 0.35 0.31 0.29 0.27 0.28
TSE:4588
40GF Score
Oncolys BioPharma Inc TSE:4588
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolys BioPharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.28% mean?
Oncolys BioPharma (TSE:4588) has a Institutional Ownership of 0.28% as of Aug. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's Institutional Ownership too high?
Oncolys BioPharma's current Institutional Ownership is 0.28%. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Institutional Ownership compare to VRTX and REGN?
Oncolys BioPharma's Institutional Ownership of 0.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current Institutional Ownership is 0.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円355.75, compared to a current price of 円3,490.00 — trading 881% above its estimated fair value. The current Institutional Ownership is 0.28%. Oncolys BioPharma's overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Institutional Ownership is 0.28% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?

Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued. The current stock price of 円3,490.00 is trading 881% above its estimated GF Value™ of 円355.75. GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.

Key valuation signals for TSE:4588:

  • Institutional Ownership: 0.28%
  • GF Value™: 円355.75 vs. price of 円3,490.00 (881% above fair value)
  • GF Score™: 40/100 with 8 warning signs

No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncolys BioPharma Business Description

Address 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score

Get the complete analysis for TSE:4588

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,490.00
Price
円355.75
GF Value